Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07585266 | A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) | recruiting | Phase 3 | 800 | GlaxoSmithKlineINDUSTRY | 15 | Sep 24, 2026 | clinicaltrials |
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | recruiting | Phase 3 | 40 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT07379047 | Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)(GISTAR-1) | recruiting | Phase 2 / Phase 3 | 255 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Jun 10, 2026 | clinicaltrials |
| NCT03673501 | A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib(INTRIGUE) | active not recruiting | Phase 3 | 453 | Deciphera Pharmaceuticals, LLCINDUSTRY | 22 | Feb 5, 2026 | clinicaltrials |
| NCT05734105 | A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib(INSIGHT) | active not recruiting | Phase 3 | 54 | Deciphera Pharmaceuticals, LLCINDUSTRY | 15 | Dec 17, 2025 | clinicaltrials |
| NCT04409223 | Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib | terminated | Phase 3 | 185 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT02260505 | Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)(ImadGist) | completed | Phase 3 | 136 | Centre Leon BerardOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05970900 | Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST(PIRKER) | not yet recruiting | Phase 3 | 23 | Fujian Medical University Union HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT00812240 | Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | terminated | Phase 3 | 335 | AB ScienceINDUSTRY | 3 | Feb 1, 2023 | clinicaltrials |
| NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies(INVICTUS) | completed | Phase 3 | 129 | Deciphera Pharmaceuticals, LLCINDUSTRY | 13 | Nov 21, 2022 | clinicaltrials |
| NCT03465722 | (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | completed | Phase 3 | 476 | Blueprint Medicines CorporationINDUSTRY | 18 | Oct 6, 2022 | clinicaltrials |
| NCT04761172 | NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours | unknown | Phase 2 / Phase 3 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT01271712 | Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)(GRID) | completed | Phase 3 | 199 | BayerINDUSTRY | 17 | Jan 29, 2021 | clinicaltrials |
| NCT01694277 | Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib | completed | Phase 3 | 258 | AB ScienceINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT03426722 | L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors | completed | Phase 3 | 4 | Asan Medical CenterOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT01151852 | Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT | completed | Phase 3 | 81 | Asan Medical CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT00103168 | Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor | completed | Phase 3 | 908 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 9, 2018 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT00324987 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor(S0502) | terminated | Phase 3 | 12 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2017 | clinicaltrials |
| NCT01289028 | Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. | completed | Phase 3 | 125 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 2, 2017 | clinicaltrials |
| NCT02866045 | EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs | unknown | Phase 3 | 104 | Unity Health TorontoOTHER | 1 | Aug 15, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01462994 | Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) | completed | Phase 3 | 25 | Technical University of MunichOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT02576080 | Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index(GIGIST) | unknown | Phase 3 | 80 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Oct 15, 2015 | clinicaltrials |
| NCT00293124 | Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors | completed | Phase 3 | 125 | Central European Cooperative Oncology GroupOTHER | 10 | Aug 13, 2015 | clinicaltrials |
| NCT00009906 | Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | terminated | Phase 3 | 748 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00685828 | Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor | unknown | Phase 3 | 946 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jul 4, 2014 | clinicaltrials |
| NCT02103322 | Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions | completed | Phase 2 / Phase 3 | 48 | Amneal Pharmaceuticals, LLCINDUSTRY | 1 | Jun 27, 2014 | clinicaltrials |
| NCT00751036 | Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg(MACS0375) | terminated | Phase 3 | 94 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 26, 2014 | clinicaltrials |
| NCT00367861 | Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance | completed | Phase 3 | 564 | Centre Leon BerardOTHER | 1 | Feb 24, 2014 | clinicaltrials |
| NCT01031628 | Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients | terminated | Phase 3 | 5 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 9, 2013 | clinicaltrials |
| NCT00041197 | Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery | completed | Phase 3 | 732 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00688766 | Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib | terminated | Phase 3 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 0 | Dec 11, 2012 | clinicaltrials |
| NCT00956072 | Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate | terminated | Phase 3 | 12 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00471328 | Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib(ENEST) | completed | Phase 3 | 248 | Novartis PharmaceuticalsINDUSTRY | 13 | Jun 12, 2012 | clinicaltrials |
| NCT00372567 | Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors | terminated | Phase 3 | 69 | PfizerINDUSTRY | 7 | Mar 17, 2011 | clinicaltrials |
| NCT00075218 | A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) | completed | Phase 3 | 361 | PfizerINDUSTRY | 11 | Sep 28, 2009 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials